Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and HEMANGEOL.
Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Joseph Castro Nuveen LLC | 57,950 | $825,787.26 | $2.21M | $1.39M | 168.08% |
Li Peng China Universal Asset Management Co. Ltd. | 4,759 | $83,497.22 | $182,555.24 | $99,058.02 | 118.64% |
Ana-Maria Ignat Covestor Ltd | 28 | $691.04 | $1,079.4 | $388.36 | 56.2% |
| JMP James M. Perkins Quantum Private Wealth LLC | 11,500 | $30,130 | $431,250 | $401,120 | 1,331.3% |
| IC Irene Chou Panoramic Capital LLC | 185,000 | $4.57M | $7.21M | $2.65M | 57.96% |
| Biotechnology Industry | Healthcare Sector | Sean E. Brynjelsen CEO | NASDAQ (NMS) Exchange | 29772L108 CUSIP |
| US Country | 44 Employees | - Last Dividend | - Last Split | 13 Nov 2018 IPO Date |
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company with a focused mission of developing, acquiring, and bringing to market pharmaceutical products aimed at treating rare diseases. Founded in 2017 and headquartered in Deer Park, Illinois, Eton Pharmaceuticals identifies unmet medical needs in the rare disease space and addresses them through innovative treatment solutions. The company's strategy underscores its commitment to improving the lives of patients, especially children suffering from complex and rare conditions that require specialized therapeutic interventions.
ALKINDI SPRINKLE stands out as a unique replacement therapy specifically formulated for managing adrenocortical insufficiency in children under the age of 17. This essential treatment offers a lifeline for young patients dealing with this rare condition, ensuring they receive the necessary hormonal support for everyday health and well-being.
Carglumic Acid is approved for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency. This product plays a critical role in managing a condition that can lead to dangerous levels of ammonia in the blood, presenting a vital solution for affected individuals.
This therapeutic option is targeted at treating homocystinuria, a rare disorder affecting the metabolism of the amino acid methionine. Betaine Anhydrous helps reduce harmful levels of homocysteine in the blood, thereby mitigating potential complications and improving the quality of life for those with homocystinuria.
Nitisinone is prescribed for the treatment of hereditary tyrosinemia type 1, a genetic disorder that can lead to severe liver and kidney problems. By using Nitisinone, patients can manage the effects of the condition, preventing significant organ damage and enhancing longevity and life quality.
As a novel solution for the emergency treatment of adrenal crisis, the Zeneo hydrocortisone autoinjector is a significant advancement in the care of patients with chronic adrenal insufficiency. This device empowers patients and caregivers by providing a quick, effective, and easy-to-use means of administering life-saving medication during a crisis.